Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

287
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
287
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Hematological oncology·2026
Same author

Blood-based epigenetic instability linked to human aging and disease.

Nature communications·2026
Same author

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Cancer discovery·2026
Same author

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Blood advances·2026
Same author

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Blood advances·2025

Related Experiment Video

Updated: Nov 5, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.2K

Treatment resistance in diffuse large B-cell lymphoma.

Michael Y He1, Robert Kridel2,3,4

  • 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Leukemia
|May 21, 2021
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) treatment resistance affects many patients. This review explores resistance mechanisms and strategies to improve outcomes for diffuse large B-cell lymphoma patients.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Related Experiment Videos

Last Updated: Nov 5, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.2K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype.
  • While 60-70% of patients achieve cure with frontline therapy, many face treatment resistance and poor outcomes.
  • Current therapeutic strategies have shown limited success in overcoming resistance.

Purpose of the Study:

  • To review the conceptual sources of treatment resistance in DLBCL.
  • To provide molecular insights into resistance mechanisms against current DLBCL treatments.
  • To highlight strategies for managing DLBCL treatment resistance.

Main Methods:

  • Literature review of conceptual sources of resistance.
  • Detailed analysis of molecular mechanisms of resistance.
  • Exploration of preventive and interventional strategies.

Main Results:

  • Treatment resistance in DLBCL stems from various conceptual sources.
  • Specific molecular mechanisms underlie resistance to current therapies.
  • Potential strategies for managing resistance include preventive and interventional approaches.

Conclusions:

  • Understanding DLBCL treatment resistance is crucial for improving patient outcomes.
  • Molecular insights are key to developing effective resistance management strategies.
  • A combination of preventive and interventional approaches may optimize treatment for resistant DLBCL.